Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia

Zoetis Inc. (NYSE:ZTS) is one of the oversold stocks to buy right now. On May 28, Zoetis received approval from the UK’s Veterinary Medicines Directorate for Lenivia (izenivetmab), a new long-acting monoclonal antibody therapy for alleviating osteoarthritis pain in dogs. Administered as a single injection, the treatment targets nerve growth factor to provide effective pain relief and improved mobility for up to three months.

Osteoarthritis is a prevalent, chronic joint disease affecting nearly 40% of dogs, significantly impacting their quality of life, mobility, and behavior. By offering a long-acting injectable option, Lenivia provides veterinary professionals with a flexible tool to support sustained comfort and manage pain as part of an individualized care plan.

This approval represents a major milestone in the company’s commitment to veterinary innovation and its expanding portfolio of monoclonal antibody therapies. Lenivia is expected to serve as a key advancement in canine pain management, helping address the significant unmet medical needs of dogs suffering from progressive joint conditions.

Zoetis (ZTS) Receives UK Approval for Long-Acting Osteoarthritis Pain Therapy Lenivia

Pixabay/Public Domain

Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments.

While we acknowledge the risk and potential of ZTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZTS and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1